PET/CT for Trop2 ADC Response Evaluation Cancers
Recruiting · NCT07046689 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
68Ga-MY6349 PET/CT
What this trial is about
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- adult patients (aged 18 years or order)
- histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports
- presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
- willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee
Exclusion criteria
- Evidence of significantly impaired hepatic or renal function
- Estimated life expectancy of less than 3 months
Where it is running
1 location listed.
- The First Affiliated Hospital of Xiamen University - Xiamen, Fujian, China